{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:44:08Z","timestamp":1785451448462,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.diabres.2025.113072","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:16:51Z","timestamp":1766506611000},"page":"113072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin"],"prefix":"10.1016","volume":"231","author":[{"given":"Yoshihiro","family":"Iwasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6300-9112","authenticated-orcid":false,"given":"Takenobu","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9639-5470","authenticated-orcid":false,"given":"Takefumi","family":"Kishimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8213-7999","authenticated-orcid":false,"given":"Takao","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2025.113072_b0005","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","article-title":"Diabetes and atherosclerosis: epidemiology, pathophysiology, and management","volume":"287","author":"Beckman","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2025.113072_b0010","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4239\/wjd.v6.i13.1246","article-title":"Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research","volume":"6","author":"Leon","year":"2015","journal-title":"World J Diabetes"},{"key":"10.1016\/j.diabres.2025.113072_b0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000977","article-title":"Levels of ankle-brachial index and the risk of diabetes mellitus complications","volume":"8","author":"Alves-Cabratosa","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.diabres.2025.113072_b0020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12933-018-0763-3","article-title":"Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies","volume":"17","author":"Kaur","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2025.113072_b0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/CLEP.S391749","article-title":"Associations between mean HbA1c, HbA1c variability, and both mortality and macrovascular complications in patients with diabetes mellitus: a registry-based cohort study","volume":"15","author":"Tan","year":"2023","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.diabres.2025.113072_b0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.113072_b0035","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1210\/clinem\/dgae038","article-title":"Tirzepatide improved markers of islet cell function and insulin sensitivity in people with T2D (SURPASS-2)","volume":"109","author":"Frias","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabres.2025.113072_b0040","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s13300-023-01398-1","article-title":"Time to reach glycaemic and body weight loss thresholds with tirzepatide in patients with type 2 diabetes: a pre-planned exploratory analysis of SURPASS-2 and SURPASS-3","volume":"14","author":"Viljoen","year":"2023","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2025.113072_b0045","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.113072_b0050","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.diabres.2025.113072_b0055","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.113072_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102489","article-title":"Tirzepatide: a novel cardiovascular protective agent in type 2 diabetes mellitus and obesity","volume":"49","author":"Sardar","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.diabres.2025.113072_b0065","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2025.113072_b0070","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/17512433.2024.2310070","article-title":"Revolutionizing diabetes care: unveiling tirzepatide\u2019s potential in glycemic control and beyond","volume":"17","author":"Sood","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.diabres.2025.113072_b0075","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1464-5491.1995.tb02055.x","article-title":"Comparing the incidence of lower extremity amputations across the world: the global lower extremity amputation study","volume":"12","author":"Unwin","year":"1995","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2025.113072_b0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1046\/j.1365-2168.2000.01344.x","article-title":"Epidemiology of lower extremity amputation in centres in Europe, North America and East Asia","volume":"87","author":"Unwin","year":"2000","journal-title":"J Br Surg"},{"key":"10.1016\/j.diabres.2025.113072_b0085","article-title":"Major lower limb amputations: recognizing pitfalls","volume":"13","author":"Pran","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.diabres.2025.113072_b0090","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","article-title":"Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial","volume":"6","author":"Bonaca","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2025.113072_b0095","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejvs.2021.05.025","article-title":"Effects of statin therapy and dose on cardiovascular and limb outcomes inperipheral arterial disease: a systematic review and meta-analysis","volume":"62","author":"Sofat","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.diabres.2025.113072_b0100","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/jcm13061670","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure with malnutrition, frailty, sarcopenia, or cachexia","volume":"13","author":"Horiuchi","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabres.2025.113072_b0105","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9305","article-title":"Comparative outcomes of empagliflozin to dapagliflozin in patients with heart failure","volume":"7","author":"Modzelewski","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabres.2025.113072_b0110","doi-asserted-by":"crossref","first-page":"37510","DOI":"10.1161\/JAHA.124.037510","article-title":"Comparative outcomes of glucagon-like peptide-1 receptor agonists to dipeptidyl peptidase 4 inhibitors in patients with heart failure and type 2 diabetes","volume":"14","author":"Kishimori","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabres.2025.113072_b0115","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat Simul Comput"},{"key":"10.1016\/j.diabres.2025.113072_b0120","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2174\/1570180820666230130153219","article-title":"Tirzepatide: a first-in-class twincretin for the management of type 2 diabetes","volume":"21","author":"Jaswal","year":"2024","journal-title":"Lett Drug Des Discov"},{"key":"10.1016\/j.diabres.2025.113072_b0125","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2025.113072_b0130","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12933-020-01118-0","article-title":"Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor","volume":"19","author":"Lee","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2025.113072_b0135","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.2337\/dc20-0267","article-title":"Sodium-glucose cotransporter 2 inhibitors and the risk of below-knee amputation: a multicenter observational study","volume":"43","author":"Yu","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.113072_b0140","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00125-021-05497-1","article-title":"Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2025.113072_b0145","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1111\/dom.15721","article-title":"Incretin-based therapy and the risk of diabetic foot ulcers and related events","volume":"26","author":"Werkman","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.113072_b0150","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2025.113072_b0155","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2025.113072_b0160","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2025.113072_b0165","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2025.113072_b0170","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1675552","article-title":"GLP-1 receptor agonists: exploration of transformation from metabolic regulation to multi-organ therapy","volume":"16","author":"Gong","year":"2025","journal-title":"Front Pharmacol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725010873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725010873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:17:12Z","timestamp":1769696232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725010873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":34,"alternative-id":["S0168822725010873"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.113072","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.113072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113072"}}